Bayer to acquire 100 per cent of the shares of China-based Dihon
Pharmaceutical Group Co., Ltd., a privately held pharmaceutical company
specializing primarily in over-the-counter (OTC) and herbal traditional
Chinese medicine (TCM) products.
Dihon is a leading player in China's OTC industry with products such as Kang Wang for the treatment of dandruff and other scalp disorders and Pi Kang Wang, an anti-fungal cream, as well as TCM product Dan E Fu Kang for the treatment of various women’s health indications.
Financial details have not been disclosed. The transaction is subject to fulfilment of certain conditions, including merger control clearance, and is expected to close in the second half of 2014.
Dihon is a leading player in China's OTC industry with products such as Kang Wang for the treatment of dandruff and other scalp disorders and Pi Kang Wang, an anti-fungal cream, as well as TCM product Dan E Fu Kang for the treatment of various women’s health indications.
Financial details have not been disclosed. The transaction is subject to fulfilment of certain conditions, including merger control clearance, and is expected to close in the second half of 2014.
No comments:
Post a Comment